These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 17134653)
21. Mechanism of resistance of African trypanosomes to cytotoxic human HDL. Hager KM; Hajduk SL Nature; 1997 Feb; 385(6619):823-6. PubMed ID: 9039915 [TBL] [Abstract][Full Text] [Related]
22. Drug transport and drug resistance in African trypanosomes. Mäser P; Lüscher A; Kaminsky R Drug Resist Updat; 2003 Oct; 6(5):281-90. PubMed ID: 14643298 [TBL] [Abstract][Full Text] [Related]
23. Uptake of the nitroimidazole drug megazol by African trypanosomes. Barrett MP; Fairlamb AH; Rousseau B; Chauvière G; Perié J Biochem Pharmacol; 2000 Mar; 59(6):615-20. PubMed ID: 10677577 [TBL] [Abstract][Full Text] [Related]
24. Current chemotherapy of human African trypanosomiasis. Docampo R; Moreno SN Parasitol Res; 2003 Jun; 90 Supp 1():S10-3. PubMed ID: 12811544 [TBL] [Abstract][Full Text] [Related]
26. Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. Carter NS; Berger BJ; Fairlamb AH J Biol Chem; 1995 Nov; 270(47):28153-7. PubMed ID: 7499305 [TBL] [Abstract][Full Text] [Related]
27. Interaction of monobenzamidine-linked trypanocides with the Trypanosoma brucei P2 aminopurine transporter. Stewart ML; Boussard C; Brun R; Gilbert IH; Barrett MP Antimicrob Agents Chemother; 2005 Dec; 49(12):5169-71. PubMed ID: 16304196 [TBL] [Abstract][Full Text] [Related]
28. A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Mäser P; Sütterlin C; Kralli A; Kaminsky R Science; 1999 Jul; 285(5425):242-4. PubMed ID: 10398598 [TBL] [Abstract][Full Text] [Related]
29. The role of Trypanosoma brucei MRPA in melarsoprol susceptibility. Alibu VP; Richter C; Voncken F; Marti G; Shahi S; Renggli CK; Seebeck T; Brun R; Clayton C Mol Biochem Parasitol; 2006 Mar; 146(1):38-44. PubMed ID: 16343658 [TBL] [Abstract][Full Text] [Related]
30. Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Mackey ZB; Baca AM; Mallari JP; Apsel B; Shelat A; Hansell EJ; Chiang PK; Wolff B; Guy KR; Williams J; McKerrow JH Chem Biol Drug Des; 2006 May; 67(5):355-63. PubMed ID: 16784460 [TBL] [Abstract][Full Text] [Related]
31. Trypanosoma brucei: expression of multiple purine transporters prevents the development of allopurinol resistance. Natto MJ; Wallace LJ; Candlish D; Al-Salabi MI; Coutts SE; de Koning HP Exp Parasitol; 2005 Feb; 109(2):80-6. PubMed ID: 15687014 [TBL] [Abstract][Full Text] [Related]
32. Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human African trypanosomiasis with natural products (Review). Gehrig S; Efferth T Int J Mol Med; 2008 Oct; 22(4):411-9. PubMed ID: 18813846 [TBL] [Abstract][Full Text] [Related]
33. Detection of arsenical drug resistance in Trypanosoma brucei with a simple fluorescence test. Stewart ML; Krishna S; Burchmore RJ; Brun R; de Koning HP; Boykin DW; Tidwell RR; Hall JE; Barrett MP Lancet; 2005 Aug 6-12; 366(9484):486-7. PubMed ID: 16084257 [TBL] [Abstract][Full Text] [Related]
34. Unsaturated Mannich bases active against multidrug-resistant Trypanosoma brucei brucei strains. Wenzel IN; Wong PE; Maes L; Müller TJ; Krauth-Siegel RL; Barrett MP; Davioud-Charvet E ChemMedChem; 2009 Mar; 4(3):339-51. PubMed ID: 19219843 [TBL] [Abstract][Full Text] [Related]
35. The diamidine diminazene aceturate is a substrate for the high-affinity pentamidine transporter: implications for the development of high resistance levels in trypanosomes. Teka IA; Kazibwe AJ; El-Sabbagh N; Al-Salabi MI; Ward CP; Eze AA; Munday JC; Mäser P; Matovu E; Barrett MP; de Koning HP Mol Pharmacol; 2011 Jul; 80(1):110-6. PubMed ID: 21436312 [TBL] [Abstract][Full Text] [Related]
36. Biosynthesis and uptake of thiamine (vitamin B1) in bloodstream form Trypanosoma brucei brucei and interference of the vitamin with melarsen oxide activity. Stoffel SA; Rodenko B; Schweingruber AM; Mäser P; de Koning HP; Schweingruber ME Int J Parasitol; 2006 Feb; 36(2):229-36. PubMed ID: 16375907 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of nucleoside hydrolase inhibitors for treatment of African trypanosomiasis. Berg M; Kohl L; Van der Veken P; Joossens J; Al-Salabi MI; Castagna V; Giannese F; Cos P; Versées W; Steyaert J; Grellier P; Haemers A; Degano M; Maes L; de Koning HP; Augustyns K Antimicrob Agents Chemother; 2010 May; 54(5):1900-8. PubMed ID: 20194690 [TBL] [Abstract][Full Text] [Related]
38. Chemical validation of GPI biosynthesis as a drug target against African sleeping sickness. Smith TK; Crossman A; Brimacombe JS; Ferguson MA EMBO J; 2004 Nov; 23(23):4701-8. PubMed ID: 15526036 [TBL] [Abstract][Full Text] [Related]
39. High-throughput decoding of antitrypanosomal drug efficacy and resistance. Alsford S; Eckert S; Baker N; Glover L; Sanchez-Flores A; Leung KF; Turner DJ; Field MC; Berriman M; Horn D Nature; 2012 Jan; 482(7384):232-6. PubMed ID: 22278056 [TBL] [Abstract][Full Text] [Related]
40. Trypanosoma brucei CTP synthetase: a target for the treatment of African sleeping sickness. Hofer A; Steverding D; Chabes A; Brun R; Thelander L Proc Natl Acad Sci U S A; 2001 May; 98(11):6412-6. PubMed ID: 11353848 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]